shares erased a decline as a strong quarterly performance more than offset a lower profit outlook amid litigation costs. The stock rose as much as 1.2%.didn’t engage in an anticompetitive conspiracy
to delay generic versions of the HIV drugs. However, before the case went to trial, the companies reached a last-minute deal with major pharmacy chains and direct purchases. Gilead paid $525 million in settlements, according to a second-quarter earnings release, which shaved 32 cents off of per-share earnings.
España Últimas Noticias, España Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Fuente: CNBC - 🏆 12. / 72 Leer más »